Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC
Bullboard Posts
User Avatar Image
(0)
•••
Comment by arghhon Feb 10, 2010 5:00pm
371 Views
Post# 16772764

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: Earnings N

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: Earnings NFrom Bioworld July 13, 2009.

https://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=51437

", Bioniche has completed enrollment for the first Phase III trial ofUrocidin, the results of which are expected in April 2010 and will bemade publicly available in May 2010. That trial is in patients who arerefractory to treatment with BCG."

Don't know if this helps at all re: news from ENDO.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities